C-Ray Therapeutics is a leading global CRDMO dedicated to end-to-end radiopharmaceutical solutions. With 28,000 sqm of integrated R&D and cGMP manufacturing facilities, we support over 30 radioisotopes at commercial scale. We have managed over 60 projects, from preclinical to Phase III trials, and excel in securing critical isotopes like Ac-225, having supported 16 related programs. Backed by over USD 187 million in funding, we provide reliable development and manufacturing services worldwide.

FibroBiologics is a clinical-stage biotechnology company developing a robust pipeline of treatments while pursuing potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. The company holds more than 270 registered patents internationally that support a broad foundation of fibroblast-based technology and research. FibroBiologics recently expanded its Houston-based laboratory facility, which strengthens its ability to pioneer additional candidates for chronic disease–focused indications. The company’s long-term goal is to bring manufacturing in-house within its Houston facilities, which have been designed with GMP capabilities in mind. 
The company’s lead program is a novel off-the-shelf therapeutic derived from human dermal fibroblasts for chronic wounds, degenerative disc disease, multiple sclerosis and psoriasis. The company’s wound care program begins with diabetic foot ulcers but is expected to expand to other chronic and post-surgical wounds, including burn injuries. FibroBiologics is also advancing early-phase discovery initiatives in thymic involution reversal, diabetes, lupus and cancer immunotherapy. 
The company’s upcoming milestones include initiating a Phase 1/2 clinical trial in Australia evaluating CYWC628 for diabetic foot ulcers in 2026 and completion of that trial by the end of 2026. Additionally, the company is also working on completing IND-enabling studies for its psoriasis candidate CYPS317 in early 2026.

Usynova Pharmaceuticals Ltd., founded in 2020 in Shanghai, China, is a clinical stage biotechnology company focused on the discovery and clinical development of innovative medicines for treatment of autoimmune diseases and other immunological disorders. The company currently has multiple assets in Phase I or Phase II clinical studies in this area. Among them, UA026 is an oral IL-17 small molecule inhibitor in Phase I and Phase IIa studies. UA026 is a 200pM inhibitor with superb PK profile in human and preclinical species, and has the potential to be the best-in-class. UA021 is a TYK2 JH2 domain inhibitor currently in Phase II clinical trials, and it has a better safety profile likely due to its selectivity and physical properties compared with other competitors. In addition, Usynova has multiple small molecule programs in preclinical stage for autoimmune diseases. 

Novamab is a clinical-stage biotech company dedicated to creating life-changing therapies for patients through innovative VHH technology. We take pride in our highly differentiated and innovative product pipeline, which targets high-potential markets such as asthma, chronic obstructive pulmonary disease (COPD), and inflammatory bowel disease (IBD).
Our most advanced project, an inhaled IL-4R VHH, has progressed to Phase II clinical trials, while our inhaled TSLP VHH is preparing to enter Phase IB proof-of-concept studies. Additionally, we are actively developing several bispecific and oral VHH antibody products aimed at treating inflammatory bowel disease (IBD).

Aspargo Labs, is a commercial-stage pharmaceutical and medtech company converting the world’s most meaningful medications into faster acting liquid oral suspensions delivered through a proprietary, digitally connected device. The company converts solid-dose medications into liquid oral suspensions that deliver faster absorption, improved bioavailability, enhanced patient compliance, and flexible dosing compared with traditional tablets.
Its lead product, ASP-001 (sildenafil oral suspension), is a fast-acting ED treatment, achieving therapeutic effect in 5 minutes versus 30–60 minutes for tablets and delivering a higher peak plasma concentration than Viagra with a bioequivalent safety profile. ASP-001 is currently commercialized in Spain (BANDOL®), Germany, and the UK (HEZKUE®). 
Aspargo is now preparing to launch its compounded formulation through telehealth channels, supported by a leading U.S. telehealth platform. The company is also developing an oral delivery device with mobile connectivity designed to enable precise dosing, adherence monitoring, and real-time patient data.

Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMab™/ RenLite®/ RenNano®/ RenTCR-mimic™ ) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. As of June 30, 2024, approximately 150 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and nearly 50 target-nominated RenMice® licensing projects have been established with over 60 global pharmaceutical and biotech companies, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn/.

Beijing Sungen Biomedical Technology Co., Ltd. is an innovation-driven, clinical-stage biotechnology company founded in 2018, pioneering the development of First-in-Class (FIC) and Best-in-Class (BIC) antibody-based therapeutics, including mAbs, BsAbs, and ADCs. Sungen is committed to addressing critical unmet clinical needs through deep innovation in therapeutic antibodies, supported by a team of researchers and managers of successful biotechnology entrepreneur records, utilizing state-of-the-art in-house discovery and research platforms.
Of Sungen’s pipelines covering cardiovascular and tumor diseases, SGC001 is a FIC-potential mAb drug for myocardial infarction. With a target validated by renowned institutions worldwide, SGC001 is initiating a multicenter phase II clinical trial, following excellent safety and encouraging efficacy trends demonstrated in its phase I study.
In oncology, SGT003 is a BIC-potential BsAb drug targeting Treg cells for pan-cancer treatment. It has demonstrated enhanced efficacy and safety in preclinical studies of multiple solid tumor models, indicating its potential as a next-generation backbone oncology therapy. 

Ningbo NewBay Technology Development Co., Ltd. is a clinical stage biotech company, its lead asset, NB003, a c-kit inhibitor for Gastrointestinal Stromal Tumors (GIST), is in Phase 1b stage, the Phase 1a data were selected as oral presentation by the Scientific Committees for both 2023 ESMO and 2024 ASCO. 

Founded in 2017, iRegene Therapeutics (iRegene), led by a passionate team, focuses on creating pioneering allogenic therapies for major incurable diseases, such as Parkinson's disease and retina degenerative diseases.
iRegene stands out as the first-in-class biotech to integrate “AI + Chemical Induction” for precisely reprogramming cell fate and functions. By applying artificial intelligence algorithms to systems biology, iRegene identifies specific chemicals to drive iPSC differentiation and redefine their functions, resulting in an innovative cell therapy product that fulfills unmet medical needs. The production process is straightforward, without any genetic modification, thereby breaking the glass ceiling that has historically limited stem-cell-derived therapies in regenerative medicine. iRegene’s platform gives rise to the pioneering of chemically-derived cell therapy, which meets the requirements of the new generation of cell therapy: efficient, safe, easy to manufacture, and cost-effective.
iRegene’s flagship product, NouvNeu001, designed for Parkinson's Disease, exemplifies this innovation and has received approval for a combined Phase I and II clinical trial. NouvNeu001 is the world's first iPSC-derived product for Parkinson's disease, as well as the first allogenic therapy developed using the "AI + chemical induction" platform. This marks a significant milestone in iRegene's journey to redefine regenerative therapy.

Laekna is a science-driven, clinical-stage biotechnology company committed to bringing novel therapeutics to patients with metabolic diseases, cancer and liver fibrosis around the world.
As of June 30, 2025, Laekna has initiated seven clinical trials for LAE102, LAE002 (afuresertib) and other drug candidates to address unmet medical needs in obesity and cancers.
LAE102 is our internally discovered antibody against ActRIIA. Blocking Activin-ActRII pathway could promote muscle regeneration and decrease fat mass, this positions LAE102 as a promising drug candidate for achieving quality weight control. We are advancing the Phase I clinical trials for obesity indication in both China and the U.S. In November 2024, Laekna entered into a clinical collaboration agreement with Eli Lilly and Company to support and accelerate global clinical development of LAE102 for the treatment of obesity.
In addition to LAE102, LAE103 is our internally discovered ActRIIB-selective antibody, LAE123 is an ActRIIA/IIB dual antagonistic monoclonal antibody. Laekna has established a comprehensive ActRII portfolio and is actively advancing these drug candidates to clinical studies as novel therapies for muscle and other disease indications.
In the cancer area, Laekna has built a comprehensive portfolio of drug candidates including LAE002(afuresertib), LAE001 and other clinical and pre-clinical drug candidates. LAE002 (afuresertib) is a potent AKT inhibitor that inhibits all three AKT isoforms (AKT1, AKT2 and AKT3) as well as one of the only two AKT inhibitors in late-stage development for breast and prostate cancer globally. Laekna has commenced the Phase III clinical trial (AFFIRM-205) for LAE002 in patients with HR+/HER2- breast cancer and the study recruitment was completed in December 2025.
Laekna, Inc. (2105.HK) was listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”) on June 29, 2023.
For more information, please visit: https://www.laekna.com/

BoomRay Pharmaceuticals is a clinical-stage biotech company dedicated to the research and development of innovative radioligand therapies (RLTs), with a focus on precision diagnosis and treatment of cancer. BoomRay has a proprietary Covalent Targeted Radioligand (CTR) technology, first published in Nature on May 22, 2024, engineered to enhance tumor uptake, sustain tumor retention, and enable rapid clearance from healthy tissue, offering potential application across diverse targets. Driven by this cutting-edge technology platform and a top-tier scientific team, BoomRay leverages its in-house R&D capabilities to advance a proprietary, high-value pipeline of novel radioligands with "First-in-class" or "Best-in-class" potential. Their mission is to emerge as a pioneering innovator and a global leader in next-generation radiopharmaceutical theranostics.
Bo Shan, Ph.D., serves as the Chief Executive Officer and Chairman of BoomRay Pharmaceuticals. With over two decades of pharmaceutical industry experience spanning China, US and Europe, he has a proven track record of leading interdisciplinary teams to advance drug candidates from discovery to approval. Under his leadership, multiple INDs approved in both China and the U.S., and three drugs ultimately achieving market approval in China. Dr. Shan obtained his Ph.D. from Aston University in the UK and has held senior executive roles at various leading organizations, including GE Healthcare.

Shanton Pharma is a privately held late-clinical-stage biotech founded in 2016, with its lead program SAP-001 focused on unmet medical needs in patients with refractory, uncontrolled, and tophaceous gout. The company is headquartered in Singapore with research and development activities in the US, China, and Singapore.
Gout is the most common form of inflammatory arthritis, caused by too much urate in the bloodstream, with over 12 million adult patients diagnosed in the US alone. Only about half of patients on conventional Urate Lowering Therapies (ULT) sufficiently respond to or can tolerate these treatment options. It is estimated that up to 20% of US gout patients on SoC allopurinol or febuxostat are physiologically refractory to these drugs.
SAP-001 is a novel once-a-day ULT and the only oral late-stage program for refractory gout. SAP-001’s First-in-Class Mechanism of Action targets a powerful renal transporter distinct from URAT1. Based on excellent clinical outcomes in a recent US Phase 2b study in uncontrolled refractory and tophaceous gout patients, the program has the potential to become Best-in-Class in refractory/uncontrolled gout. Shanton has received Fast Track designation in the US for its program, and following a successful EOP2 meeting with FDA, SAP-001 is now Phase 3-ready.

TaiMed Biologics is a publicly listed Taiwanese biopharmaceutical company offering a compelling combination of commercial validation, late-stage clinical maturity, and platform-level upside. The company uniquely integrates (i) an FDA-approved antibody product for HIV, (ii) a Phase 2b long-acting HIV program with multi-billion-dollar market potential, and (iii) a next-generation antibody-drug conjugate (ADC) platform targeting CD4-positive immune cells. Together, these assets position TaiMed as a de-risked investment opportunity ahead of a significant valuation inflection.

TaiMed’s foundation is anchored by Trogarzo® (ibalizumab), the world’s first CD4-targeting monoclonal antibody approved for multidrug-resistant HIV. Trogarzo validates TaiMed’s antibody platform and demonstrates end-to-end capabilities spanning antibody development, GMP manufacturing, FDA regulatory execution, and global partnering—establishing a durable valuation floor.

TaiMed’s primary value driver is TMB-365/TMB-380, a long-acting, dual-antibody HIV regimen currently in Phase 2b clinical development for front-line therapy. By targeting both the host CD4 receptor and the virus, the program delivers first-in-class mechanistic synergy with potential best-in-class durability. In a global long-acting HIV market measured in tens of billions of U.S. dollars, Phase 2b represents the final entry point before Phase 3-driven re-rating, offering asymmetric upside through clinical advancement, strategic partnerships, or long-term commercialization.

OncoNano is pioneering the next frontier of cancer therapeutics using our proprietarypolymer-drug conjugate(PDC) platform. OncoNano's ON-BOARDmplatform exploits thehighly acidic tumor microenvironment, a byproduct of cancer metabolism, to maximize theintratumoraldelivery of its therapeutic cargoes. ON-BOARD" ultra pH-sensitive polymericmicelles protect payloads from systemic exposure and target tumors by responding totumor acidity. Our polymer chemistry is tunable and can be optimized for multiple types ofpayloads. The simplicity of the PDC approach eliminates the need for more complexsurface biomarkers that may limit therapeutic utility due to expression heterogeneity.
OncoNano's ON-BOARDm PDC technology advantages:
· Universal Tumor Targeting
· Protected Payload Delivery
· Precise Release at Tumor Sites
· Broader Application, potentially treating more types of cancer
The core technology has been validated in humans using a tumor imaging agent payload(Phase 3 ready asset with FDA Breakthrough and Fast Track Designations).
In addition to our ON-BOARDmplatform, our pipeline also includes a novel, clinical-stage,dual-activating STING agonist with promising Phase1 data. This study is currently enrollingPart 2 of the study (skin basket trial).
OncoNano is passionate about generating a robust oncology pipeline to advance moreprecise therapies and better patient outcomes.

AuroraMol is an early-stage molecular discovery company focused on the continuous generation of experimentally validated molecular assets with clear development potential. Addressing real-world drug discovery needs, the company has completed systematic validation across more than 20 protein targets, identifying multiple classes of candidates with novel chemical scaffolds.
AuroraMol delivers early molecular assets validated through integrated computational assessment, chemical synthesis, and biological testing, ensuring that molecules presented for partnership are supported by concrete experimental evidence and are ready for project evaluation, collaborative development, and licensing decisions.
To enable stable and repeatable asset generation, AuroraMol operates a scalable discovery system that integrates artificial intelligence and physics-based modeling with a highly reliable modular chemistry experimental platform, forming an AI+modular dry–wet closed-loop workflow. This system supports rapid iteration across design, synthesis, and validation cycles, with experimental feedback continuously guiding molecular exploration and improving asset quality.
Through this approach, AuroraMol has established reusable and scalable workflows for early molecular discovery and asset generation, supporting both focused optimization of individual assets and parallel evaluation of multiple molecular hypotheses.
For partnership and business development inquiries, please contact: bd@auroramol.com

Macrolink (MLK) is focusing on the next generation ADC product R&D. Product pipeline includes new targets (FIC) ADC and bispecific ADC (FIC) using pioneer technologies. The MLK technology platform (MlkCore) is standing out from classic ADC technologies, its innovations focus on the CQA of ADC to increase its efficacy and safety:
·Novel antibody design with high tumor penetration.
·New site-specific conjugation at the optimal position to increase blood stream circulation atability.
·Stable linker and conjugation to minimize off target toxicity.
MLK’s lead ADC candidate MC002, IND submitted in Dec. 2025. This novel ADC has demonstrated potent and sustained tumor eradication—with no relapse observed for over 90 days—across multiple solid tumors, including NSCLC, pancreatic, hepatic, cervical, gastric and prostate cancers. In the head-to-head comparative study with DS8201 (targets co-expression at similar levels), MC002 exhibited superior efficacy: complete remission and long durability. In preclinical studies, it also showed that MC002 has a longer half-life in NHP than DS8201 (8.6 days VS. 4 days) and a much better blood stream circulation stability. The GLP toxicology study is completed, and it demonstrated excellent safety profile.
MLK’s pipeline includes new target ADC and FIC bispecific ADCs. 

Founded in 2020, Immunocan is a pioneering biotechnology company transforming therapeutic R&D through its advanced mega-base gene-editing technology. The cornerstone of its innovation, the ImRobust® gene-edited animal suite, generates antibody repertoires of unparalleled diversity, offering high-potential candidates for the discovery and development of complex biologics such as ADCs and bispecific/multispecific antibodies.
Immunocan has launched a broad range of pilot programs in collaboration with pharmaceutical and biotechnology companies, with the goal of fostering long-term partnerships that drive revolutionary increases in R&D efficiency.
Committed to innovation and collaboration, Immunocan continues to develop universal antibody discovery technologies that empower its global partners to accelerate the development of next-generation therapeutics, shaping the future of medicine for unmet medical needs worldwide.

Huaota is specialized in innovative antibody program R&D in the field of complex inflammatory diseases, fibrotic disorders, and solid tumors, which is established in Shanghai in the year of 2013.
Driven by innovation and development, Huaota has built comprehensive and integrated platforms to develop novel biologics. The R&D platform at Huaota supports the identification and development of new monoclonal antibodies, bispecific antibodies, fusion proteins, ADC drugs, etc, with specialized portfolio of I&I and IO programs, of which 7 in clinical stage, 1 in NDA stage, and is planning to submit an IPO application in 2026.
Independent research and development drive innovation. Huaota has a diverse product pipeline covering therapeutic areas such as tumors and autoimmune diseases. At present, there are over twenty projects under development. Many of them have obtained IND approval and multiple clinical trials are undertaken in the United States, New Zealand, and China. In 2019, Huaota was certified as High- and New-Technology Enterprise. And it’s poised to be capable of suppling in-house antibody finished products that meet the global standards.
Huaota is seeking global partnerships through licenses and investments to collaborate and advance these projects that aim to provide high-quality, advanced biological drugs to the global market, meeting the demand for accessible and affordable biopharmaceuticals. The vision is to innovate and change the world through these efforts.

Linno Pharmaceuticals is a clinical-stage biotech company developing the next-generation pathway-selective complement inhibitors for inflammatory diseases and a proprietary BBB-penetration technology called Nano Brain-Pass (NBP) for CNS disorders.
LIN-2102, our leading clinical asset, is a potent antibody targeting properdin (aka, complement factor P), a key positive modulator of the Alternative Pathway (AP) of complement activation. Selectively targeting AP with LIN-2102 is a potentially effective and safer approach to treat a myriad of complement-mediated, especially AP-driven, diseases such as IgAN, PNH and dAMD/GA. LIN-2102 is well tolerated in human with favorable PK/PD profiles in phase 1 studies.
Linno’s NBP technology is a unique and versatile BBB-penetration module that differentiates from traditional Brain shuttle with a nanobody binding to transferrin instead of its receptor (TfR). Proof-of-concept studies have been achieved with various therapeutic modalities including peptide, protein (e.g., enzyme, neurotrophic factor, antibody) and siRNA, demonstrating advantages over the well-known TfR-binding brain shuttles. Several therapeutic candidates have been developed for the treatment of lysosome storage diseases (LSD), neurodegenerative or neuroinflammatory diseases. Among them, LIN-2003 is a BBB-penetrating ERT for metachromatic leukodystrophy (MLD), a rare demyelinating disease with very limited therapeutic options.

NeuExcell is a clinical-stage biotechnology company dedicated to developing innovative and disease-modifying treatments for neurological injuries and neurodegenerative disorders. The company has established a pioneering platform technology that enables the direct reprogramming of internal glial cells into functional neurons via an in situ conversion approach. This groundbreaking strategy is designed to address a broad spectrum of neurological conditions, including glioma, Alzheimer's disease, Parkinson's disease, and stroke. NeuExcell has advanced its three lead programs into First-in-Human clinical trials. Notably, its glioma program utilizing the proprietary NeuroD1-based gene therapy NXL-004 was initiated in March 2024. To date, 11 patients have been enrolled and have shown encouraging efficacy. It has received Orphan Drug Designation from the U.S. FDA. Supported by a robust intellectual property portfolio, NeuExcell is well positioned as an emerging leader in the field of neuroregenerative medicine.

Youcare Pharmaceutical Group was founded in 2001 and listed on the SSE STAR Market in 2020. So far, Youcare has been a fully integrated pharmaceutical leader with end-to-end capabilities spanning R&D, cGMP manufacturing, and commercialization, currently has a professional international drug R&D team of over 500 members, including over 80 doctoral holders and senior professionals with advanced academic titles.
Youcare focuses on therapeutic areas such as cardiovascular diseases, oncology, and infectious diseases. The company has established eleven core technology platforms centered on nucleic acid drugs, peptide drugs, advanced traditional Chinese medicine, high-end chemical drugs, and end-to-end AI-driven drug discovery. It has also implemented a systematic layout in underlying key technologies for nucleic acid therapeutics, including AI-based target discovery, sequence optimization design, LNP delivery, GalNAc delivery, TLP delivery, extrahepatic targeted delivery, nucleoside monomer modification, and co-capping. To date, the company has been granted over 400 patents.
Supported by leading R&D platforms and a solid IP portfolio, Youcare is actively advancing our innovative assets, notably ultra-long-acting siRNA programs (such as YKYY013/015/029/032/033), mRNA vaccines (YKYY025/026/031) and peptide inhalation (YYKK017/018). Strategic out-licensing deals for these innovative pipelines are a key focus for its next phase of international growth.

Founded in 2010, Wuhan YZY Biopharma Co., Ltd. (02496.HK) is a global biotechnology leader in treating oncology and autoimmune diseases. Specializing in innovative bispecific antibodies (BsAb), the company leverages its proprietary platforms, YBODY®, Check-BODY, and Nano-YBODY™, to develop a diverse pipeline of preclinical and clinical products. Key therapies include:
M701 (EpCAM×CD3 BsAb) for malignant pleural effusion (MPE) and malignant ascites (MA);
Y180 an innovative LAG3-Fc fusion protein designed to address key limitations of current PD-1 immunotherapies;
Y410, a Wnt/Norrin mimetic targeting Frizzled-4 (FZD4) and low-density lipoprotein receptor-related protein 5 (LRP5), is designed to address retinal nonperfusion and vascular leakage, independent of the vascular endothelial growth factor (VEGF) inhibitory signaling pathway.
Notably, M701 is in Phase II trials in China for malignant pleural effusion (MPE), with key results showing significant improvements in puncture-free survival and overall response rate, plus good tolerability.
We will pursue expedited U.S. approval via the orphan drug and conditional approval accelerated review pathway. Similarly, we will use the orphan drug designation route for rapid market access in the EU, Australia, Canada and other core regulatory jurisdictions. YZY Biopharma is actively seeking international partnerships and preparing to launch global multicenter clinical trials.
With a mission to safeguard global health, Wuhan YZY Biopharma continues to innovate and collaborate to meet urgent healthcare needs worldwide.

Humanwell Healthcare (Group) Co., Ltd. （Hereafter "Humanwell Healthcare Group"） was founded in 1993, and was listed on the Shanghai Stock Exchange in 1997. Humanwell is one of the largest pain management specialty pharma, ranked top 30 in the pharmaceutical industry in China. Humanwell has established a leading position in multiple domestic market segments including narcotic drugs, steroid hormones drugs, and Uyghur medicine. We have more than 2000 scientists and researchers working in the R&D centers in Wuhan and Yichang in China, New Jersey and St. Louis in the United States, and Aachen in Germany.
We have established an innovative pipeline in therapeutic areas such as anesthesia, respiratory, metabolic and autoimmune disorders. We are actively seeking business development and licensing opportunities and partnerships with global pharmaceutical and biotechnology companies.

Iongen Therapeutics is exclusively focused on ion channel targets, dedicated to developing next-generation pain therapeutics that address unmet clinical needs.Our robust pipeline features two lead Nav1.8 inhibitors—both with best-in-class potential—currently advancing through IND-enabling studies. Complementing these programs, we are progressing two strategic initiatives: a Nav1.7/1.8 dual inhibitor designed to deliver synergistic analgesic effects, and research into novel combinations of Nav1.8 inhibitors with other ion channel modulators. These efforts aim to achieve superior pain relief and enhanced efficacy in chronic pain management.Built on scientific rigor and clinical relevance, Iongen Therapeutics’ mission is to pioneer breakthrough therapies that redefine the standard of care for pain patients worldwide.